» Articles » PMID: 36762930

Mixed Origins: HIV Gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans

Overview
Publisher Mary Ann Liebert
Date 2023 Feb 10
PMID 36762930
Authors
Affiliations
Soon will be listed here.
Abstract

The most potent and broad HIV envelope (Env)-specific antibodies often when reverted to their inferred germline versions representing the naive B cell receptor, fail to bind Env, suggesting that the initial responding B cell population not only exclusively comprises a naive population, but also a pre-existing cross-reactive antigen-experienced B cell pool that expands following Env exposure. Previously we isolated gp120-reactive monoclonal antibodies (mAbs) from participants in HVTN 105, an HIV vaccine trial. Using deep sequencing, focused on immunoglobulin G (IgG), IgA, and IgM, VH-lineage tracking, we identified four of these mAb lineages in pre-immune peripheral blood. We also looked through the ∼7 month postvaccination bone marrow, and interestingly, several of these lineages that were found in prevaccination blood were still persistent in the postvaccination bone marrow, including the CD138+ long-lived plasma cell compartment. The majority of the pre-immune lineage members included IgM, however, IgG and IgA members were also prevalent and exhibited somatic hypermutation. These results suggest that vaccine-induced gp120-specific antibody lineages originate from both naive and cross-reactive memory B cells. ClinicalTrials.gov NCT02207920.

Citing Articles

Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.

Kaur A, Vaccari M Viruses. 2024; 16(3).

PMID: 38543734 PMC: 10974975. DOI: 10.3390/v16030368.


Highly Cross-Reactive and Protective Influenza A Virus H3N2 Hemagglutinin- and Neuraminidase-Specific Human Monoclonal Antibodies.

Piepenbrink M, Oladunni F, Nogales A, Khalil A, Fitzgerald T, Basu M Microbiol Spectr. 2023; 11(4):e0472822.

PMID: 37318331 PMC: 10433997. DOI: 10.1128/spectrum.04728-22.

References
1.
Hraber P, Seaman M, Bailer R, Mascola J, Montefiori D, Korber B . Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS. 2013; 28(2):163-9. PMC: 4042313. DOI: 10.1097/QAD.0000000000000106. View

2.
Jardine J, Ota T, Sok D, Pauthner M, Kulp D, Kalyuzhniy O . HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science. 2015; 349(6244):156-61. PMC: 4669217. DOI: 10.1126/science.aac5894. View

3.
Karray S, Juompan L, Maroun R, Isenberg D, Silverman G, Zouali M . Structural basis of the gp120 superantigen-binding site on human immunoglobulins. J Immunol. 1998; 161(12):6681-8. View

4.
Wagh K, Hahn B, Korber B . Hitting the sweet spot: exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies. Curr Opin HIV AIDS. 2020; 15(5):267-274. PMC: 7877895. DOI: 10.1097/COH.0000000000000639. View

5.
Williams W, Liao H, Moody M, Kepler T, Alam S, Gao F . HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science. 2015; 349(6249):aab1253. PMC: 4562404. DOI: 10.1126/science.aab1253. View